[1] G. K. Michalopoulos, and M. C. DeFrances, “Liver regeneration,” Science, vol. 276, no. 5309, pp. 60-6, Apr 04, 1997.
[2] M. F. Chen, T. L. Hwang, and C. F. Hung, “Human liver regeneration after major hepatectomy. A study of liver volume by computed tomography,” Ann Surg, vol. 213, no. 3, pp. 227-9, Mar, 1991.
[3] P. G. Kele, M. de Boer, E. J. van der Jagt, T. Lisman, and R. J. Porte, “Early hepatic regeneration index and completeness of regeneration at 6 months after partial hepatectomy,” Br J Surg, vol. 99, no. 8, pp. 1113-9, Aug, 2012.
[4] S. Kawasaki, M. Makuuchi, H. Matsunami, Y. Hashikura, T. Ikegami, Y. Nakazawa, H. Chisuwa, M. Terada, and S. Miyagawa, “Living related liver transplantation in adults,” Ann Surg, vol. 227, no. 2, pp. 269-74, Feb, 1998.
[5] E. K. Abdalla, M. E. Hicks, and J. N. Vauthey, “Portal vein embolization: rationale, technique and future prospects,” Br J Surg, vol. 88, no. 2, pp. 165-75, Feb, 2001.
[6] O. Farges, J. Belghiti, R. Kianmanesh, J. M. Regimbeau, R. Santoro, V. Vilgrain, A. Denys, and A. Sauvanet, “Portal vein embolization before right hepatectomy: prospective clinical trial,” Ann Surg, vol. 237, no. 2, pp. 208-17, Feb, 2003.
[7] N. Yamanaka, E. Okamoto, E. Kawamura, T. Kato, T. Oriyama, J. Fujimoto, K. Furukawa, T. Tanaka, F. Tomoda, and W. Tanaka, “Dynamics of normal and injured human liver regeneration after hepatectomy as assessed on the basis of computed tomography and liver function,” Hepatology, vol. 18, no. 1, pp. 79-85, Jul, 1993.
[8] M. K. Ju, G. H. Choi, J. S. Park, D. S. Yoon, J. Choi, M. S. Kim, and S. I. Kim, “Difference of regeneration potential between healthy and diseased liver,” Transplant Proc, vol. 44, no. 2, pp. 338-40, Mar, 2012.
[9] S. Shiina, T. Teratani, S. Obi, S. Sato, R. Tateishi, T. Fujishima, T. Ishikawa, Y. Koike, H. Yoshida, T. Kawabe, and M. Omata, “A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma,” Gastroenterology, vol. 129, no. 1, pp. 122-30, Jul, 2005.
[10] S. Shiina, R. Tateishi, T. Arano, K. Uchino, K. Enooku, H. Nakagawa, Y. Asaoka, T. Sato, R. Masuzaki, Y. Kondo, T. Goto, H. Yoshida, M. Omata, and K. Koike, “Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors,” Am J Gastroenterol, vol. 107, no. 4, pp. 569-77; quiz 578, Apr, 2012.
[11] L. Zhang, N. L. Ge, Y. Chen, X. Y. Xie, X. Yin, Y. H. Gan, B. H. Zhang, J. B. Zhang, R. X. Chen, Y. H. Wang, S. L. Ye, and Z. G. Ren, “Longterm outcomes and prognostic analysis of radiofrequency ablation for small hepatocellular carcinoma: 10-year follow-up in Chinese patients,” Med Oncol, vol. 32, no. 3, pp. 77, Mar, 2015.
[12] L. C. Bertot, M. Sato, R. Tateishi, H. Yoshida, and K. Koike, “Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review,” Eur Radiol, vol. 21, no. 12, pp. 2584-96, Dec, 2011.
[13] G. Poggi, C. Teragni, C. Gazzaruso, and G. Bernado, “Massive hepatic infarction complicating ultrasound-guided percutaneous radiofrequency thermal ablation,” Liver Int, vol. 24, no. 6, pp. 704-5, Dec, 2004.
[14] B. L. Holbert, R. L. Baron, and G. D. Dodd, 3rd, “Hepatic infarction caused by arterial insufficiency: spectrum and evolution of CT findings,” AJR Am J Roentgenol, vol. 166, no. 4, pp. 815-20, Apr, 1996.
[15] G. S. Smith, B. A. Birnbaum, and J. E. Jacobs, “Hepatic infarction secondary to arterial insufficiency in native livers: CT findings in 10 patients,” Radiology, vol. 208, no. 1, pp. 223-9, Jul, 1998.
[16] Y. S. Kim, H. Rhim, H. K. Lim, D. Choi, W. J. Lee, and S. H. Kim, “Hepatic infarction after radiofrequency ablation of hepatocellular carcinoma with an internally cooled electrode,” J Vasc Interv Radiol, vol. 18, no. 9, pp. 1126-33, Sep, 2007.
[17] X. P. Zhou, T. Lu, Y. G. Wei, and X. Z. Chen, “Liver volume variation in patients with virus-induced cirrhosis: findings on MDCT,” AJR Am J Roentgenol, vol. 189, no. 3, pp. W153-9, Sep, 2007.
[18] X. Z. Lin, Y. N. Sun, Y. H. Liu, B. S. Sheu, B. N. Cheng, C. Y. Chen, H. M. Tsai, and C. L. Shen, “Liver volume in patients with or without chronic liver diseases,” Hepatogastroenterology, vol. 45, no. 22, pp. 1069-74, Jul-Aug, 1998.
[19] M. T. Hagan, G. S. Sayuk, M. Lisker-Melman, K. M. Korenblat, T. A. Kerr, W. C. Chapman, and J. S. Crippin, “Liver volume in the cirrhotic patient: does size matter?,” Dig Dis Sci, vol. 59, no. 4, pp. 886-91, Apr, 2014.
[20] M. Patel, P. Puangsricharoen, H. M. S. Arshad, S. Garrison, W. Techasatian, M. Ghabril, K. Sandrasegaran, S. Liangpunsakul, and M. Tann, “Does providing routine liver volume assessment add value when performing CT surveillance in cirrhotic patients?,” Abdominal radiology (New York), vol. 44, no. 10, pp. 3263-3272, 2019.
[21] S. Shiina, R. Tateishi, M. Imamura, T. Teratani, Y. Koike, S. Sato, S. Obi, F. Kanai, N. Kato, H. Yoshida, M. Omata, and K. Koike, “Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors,” Liver Int, vol. 32, no. 9, pp. 1434-42, Oct, 2012.
[22] R. Tateishi, S. Shiina, T. Teratani, S. Obi, S. Sato, Y. Koike, T. Fujishima, H. Yoshida, T. Kawabe, and M. Omata, “Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases,” Cancer, vol. 103, no. 6, pp. 1201-9, Mar 15, 2005.
[23] N. Kokudo, K. Hasegawa, M. Akahane, H. Igaki, N. Izumi, T. Ichida, S. Uemoto, S. Kaneko, S. Kawasaki, Y. Ku, M. Kudo, S. Kubo, T. Takayama, R. Tateishi, T. Fukuda, O. Matsui, Y. Matsuyama, T. Murakami, S. Arii, M. Okazaki, and M. Makuuchi, “Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines),” Hepatol Res, vol. 45, no. 2, Jan, 2015.
[24] H. A. Edmondson, and P. E. Steiner, “Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies,” Cancer, vol. 7, no. 3, pp. 462-503, May, 1954.
[25] T. Wake, R. Tateishi, R. Nakagomi, N. Fujiwara, M. N. Kinoshita, T. Nakatsuka, M. Sato, T. Minami, K. Uchino, K. Enooku, H. Nakagawa, Y. Asaoka, Y. Tanaka, S. Shiina, and K. Koike, “Ischemic complications after percutaneous radiofrequency ablation of liver tumors: Liver volume loss and recovery,” Hepatol Res, vol. 49, no. 4, pp. 453-461, Apr, 2019.
[26] S. Ohshima, “Volume analyzer SYNAPSE VINCENT for liver analysis,” J Hepatobiliary Pancreat Sci, vol. 21, no. 4, pp. 235-8, Apr, 2014.
[27] T. Takamoto, T. Hashimoto, S. Ogata, K. Inoue, Y. Maruyama, A. Miyazaki, and M. Makuuchi, “Planning of anatomical liver segmentectomy and subsegmentectomy with 3-dimensional simulation software,” Am J Surg, vol. 206, no. 4, pp. 530-8, Oct, 2013.
[28] K. Urata, S. Kawasaki, H. Matsunami, Y. Hashikura, T. Ikegami, S. Ishizone, Y. Momose, A. Komiyama, and M. Makuuchi, “Calculation of child and adult standard liver volume for liver transplantation,” Hepatology, vol. 21, no. 5, pp. 1317-21, May, 1995.
[29] M. Saegusa, Y. Takano, and M. Okudaira, “Human hepatic infarction: histopathological and postmortem angiological studies,” Liver, vol. 13, no. 5, pp. 239-45, Oct, 1993.
[30] M. Akahane, H. Koga, N. Kato, H. Yamada, K. Uozumi, R. Tateishi, T. Teratani, S. Shiina, and K. Ohtomo, “Complications of percutaneous radiofrequency ablation for hepato-cellular carcinoma: imaging spectrum and management,” Radiographics, vol. 25 Suppl 1, pp. S57- 68, Oct, 2005.
[31] B. S. Kim, T. K. Kim, J. S. Kim, M. G. Lee, J. H. Kim, K. W. Kim, K. B. Sung, P. N. Kim, H. K. Ha, S. G. Lee, and W. Kang, “Hepatic venous congestion after living donor liver transplantation with right lobe graft: two-phase CT findings,” Radiology, vol. 232, no. 1, pp. 173- 80, Jul, 2004.
[32] M. L. Wells, and S. K. Venkatesh, “Congestive hepatopathy,” Abdominal radiology (New York), vol. 43, no. 8, pp. 2037-2051, 2018.
[33] M. Tani, T. Tomiya, S. Yamada, S. Hayashi, K. Yahata, Y. Tamura, M. Akiyama, S. Kawai, N. Masaki, K. Fujiwara, and et al., “Regulating factors of liver regeneration after hepatectomy,” Cancer Chemother Pharmacol, vol. 33 Suppl, pp. S29-32, 1994.
[34] S. Yan, B. Zhou, Q. Zhang, Z. Li, Y. Shao, H. Chen, and S. Zheng, “Hepatic venous occlusion causes more impairment after reperfusion compared with portal clamping in a murine model,” J Surg Res, vol. 169, no. 1, pp. 117-24, Jul, 2011.
[35] E. Koc, S. Topaloglu, A. Calik, C. Sokmensuer, S. Abdullazade, E. Karabulut, and B. Piskin, “Hepatic microcirculation in inflow and inflow-outflow occlusion of the liver,” Transplant Proc, vol. 45, no. 2, pp. 474-9, Mar, 2013.
[36] M. Kimura, M. Kataoka, Y. Kuwabara, A. Sato, M. Sugiura, and Y. Fujii, “Real-time energy metabolism of intestine during arterial versus venous occlusion in the rat,” J Gastroenterol, vol. 38, no. 9, pp. 849-53, 2003.
[37] R. K. Seeto, B. Fenn, and D. C. Rockey, “Ischemic hepatitis: clinical presentation and pathogenesis,” Am J Med, vol. 109, no. 2, pp. 109- 13, Aug 1, 2000.
[38] E. B. Tapper, N. Sengupta, and A. Bonder, “The Incidence and Outcomes of Ischemic Hepatitis: A Systematic Review with Metaanalysis,” Am J Med, vol. 128, no. 12, pp. 1314-21, Dec, 2015.
[39] A. P. Thrift, H. B. El-Serag, and F. Kanwal, “Global epidemiology and burden of HCV infection and HCV-related disease,” Nat Rev Gastroenterol Hepatol, vol. 14, no. 2, pp. 122-132, Feb, 2017.
[40] R. G. Simonetti, C. Camma, F. Fiorello, M. Cottone, M. Rapicetta, L. Marino, G. Fiorentino, A. Craxi, A. Ciccaglione, R. Giuseppetti, and et al., “Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study,” Ann Intern Med, vol. 116, no. 2, pp. 97-102, Jan 15, 1992.
[41] H. B. El-Serag, “Epidemiology of viral hepatitis and hepatocellular carcinoma,” Gastroenterology, vol. 142, no. 6, pp. 1264-1273.e1, May, 2012.
[42] T. Poynard, P. Bedossa, and P. Opolon, “Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups,” Lancet, vol. 349, no. 9055, pp. 825-32, Mar 22, 1997.
[43] H. Yoshida, R. Tateishi, Y. Arakawa, M. Sata, S. Fujiyama, S. Nishiguchi, H. Ishibashi, G. Yamada, O. Yokosuka, Y. Shiratori, and M. Omata, “Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C,” Gut, vol. 53, no. 3, pp. 425-30, Mar, 2004.
[44] Y. Shiratori, S. Shiina, T. Teratani, M. Imamura, S. Obi, S. Sato, Y. Koike, H. Yoshida, and M. Omata, “Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus,” Ann Intern Med, vol. 138, no. 4, pp. 299-306, Feb 18, 2003.
[45] V. Mazzaferro, R. Romito, M. Schiavo, L. Mariani, T. Camerini, S. Bhoori, L. Capussotti, F. Calise, R. Pellicci, G. Belli, A. Tagger, M. Colombo, F. Bonino, P. Majno, and J. M. Llovet, “Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis,” Hepatology, vol. 44, no. 6, pp. 1543-54, Dec, 2006.
[46] T. Minami, R. Tateishi, S. Shiina, R. Nakagomi, M. Kondo, N. Fujiwara, S. Mikami, M. Sato, K. Uchino, K. Enooku, H. Nakagawa, Y. Asaoka, Y. Kondo, H. Yoshida, and K. Koike, “Comparison of improved prognosis between hepatitis B- and hepatitis C-related hepatocellular carcinoma,” Hepatol Res, vol. 45, no. 10, pp. E99-e107, Oct, 2015.
[47] L. Fartoux, F. Degos, C. Trépo, O. Goria, P. Calès, A. Tran, C. Buffet, T. Poynard, D. Capron, J.-J. Raabe, D. Roulot, S. Naveau, J.-D. Grange, R. E. Poupon, R. Poupon, and L. Serfaty, “Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial,” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol. 5, no. 4, pp. 502-507, 2007.
[48] R. Idilman, N. De Maria, A. Colantoni, A. Dokmeci, and D. H. Van Thiel, “Interferon treatment of cirrhotic patients with chronic hepatitis C,” Journal of viral hepatitis, vol. 4, no. 2, pp. 81-91, 1997.
[49] H. Toyoda, K. Chayama, F. Suzuki, K. Sato, T. Atarashi, T. Watanabe, M. Atsukawa, A. Naganuma, K. Notsumata, Y. Osaki, M. Nakamuta, K. Takaguchi, S. Saito, K. Kato, D. Pugatch, M. Burroughs, R. Redman, K. Alves, T. J. Pilot-Matias, R. K. Oberoi, B. Fu, and H. Kumada, “Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection,” Hepatology, Sep 2, 2017.
[50] H. Kumada, T. Watanabe, F. Suzuki, K. Ikeda, K. Sato, H. Toyoda, M. Atsukawa, A. Ido, A. Takaki, N. Enomoto, K. Kato, K. Alves, M. Burroughs, R. Redman, D. Pugatch, T. J. Pilot-Matias, P. Krishnan, R. K. Oberoi, W. Xie, and K. Chayama, “Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection,” J Gastroenterol, vol. 53, no. 4, pp. 566-575, Apr, 2018.
[51] K. Chayama, F. Suzuki, Y. Karino, Y. Kawakami, K. Sato, T. Atarashi, A. Naganuma, T. Watanabe, Y. Eguchi, H. Yoshiji, M. Seike, Y. Takei, K. Kato, K. Alves, M. Burroughs, R. Redman, D. L. Pugatch, T. J. Pilot-Matias, P. Krishnan, R. K. Oberoi, W. Xie, and H. Kumada, “Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis,” J Gastroenterol, vol. 53, no. 4, pp. 557-565, Apr, 2018.
[52] S. B. Heymsfield, T. Fulenwider, B. Nordlinger, R. Barlow, P. Sones, and M. Kutner, “Accurate measurement of liver, kidney, and spleen volume and mass by computerized axial tomography,” Ann Intern Med, vol. 90, no. 2, pp. 185-7, Feb, 1979.
[53] J. Kalkmann, M. Forsting, and J. Stattaus, “Liver volume variations as a parameter to assess therapy response in advanced metastatic liver disease,” Onkologie, vol. 34, no. 1-2, pp. 30-4, 2011.
[54] L. Dubus, M. Gayet, M. Zappa, L. Abaleo, A. De Cooman, G. Orieux, and V. Vilgrain, “Comparison of semi-automated and manual methods to measure the volume of liver tumours on MDCT images,” Eur Radiol, vol. 21, no. 5, pp. 996-1003, May, 2011.
[55] J. N. Vauthey, E. K. Abdalla, D. A. Doherty, P. Gertsch, M. J. Fenstermacher, E. M. Loyer, J. Lerut, R. Materne, X. Wang, A. Encarnacion, D. Herron, C. Mathey, G. Ferrari, C. Charnsangavej, K. A. Do, and A. Denys, “Body surface area and body weight predict total liver volume in Western adults,” Liver Transpl, vol. 8, no. 3, pp. 233- 40, Mar, 2002.
[56] W.-B. Du, X.-P. Pan, and L.-J. Li, “Prognostic models for acute liver failure,” Hepatobiliary & pancreatic diseases international : HBPD INT, vol. 9, no. 2, pp. 122-128, 2010.
[57] Y. M. Li, F. Lv, X. Xu, H. Ji, W. T. Gao, T. J. Lei, G. B. Ren, Z. L. Bai, and Q. Li, “Evaluation of liver functional reserve by combining Dsorbitol clearance rate and CT measured liver volume,” World J Gastroenterol, vol. 9, no. 9, pp. 2092-5, Sep, 2003.
[58] R. Tu, L.-P. Xia, A.-L. Yu, and L. Wu, “Assessment of hepatic functional reserve by cirrhosis grading and liver volume measurement using CT,” World journal of gastroenterology, vol. 13, no. 29, pp. 3956-3961, 2007.
[59] K. Deterding, C. Honer Zu Siederdissen, K. Port, P. Solbach, L. Sollik, J. Kirschner, C. Mix, J. Cornberg, D. Worzala, H. Mix, M. P. Manns, M. Cornberg, and H. Wedemeyer, “Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies,” Aliment Pharmacol Ther, vol. 42, no. 7, pp. 889- 901, Oct, 2015.
[60] A. Z. Khan, and S. S. Mudan, “Liver regeneration: mechanisms, mysteries and more,” ANZ journal of surgery, vol. 77, no. 1-2, pp. 9- 14, Jan-Feb, 2007.
[61] R. Sugimoto, M. Iwasa, N. Hara, Y. Tamai, K. Yoshikawa, S. Ogura, H. Tanaka, A. Eguchi, N. Yamamoto, Y. Kobayashi, H. Hasegawa, and Y. Takei, “Changes in liver function and body composition by directacting antiviral therapy for hepatitis C virus infection,” Hepatol Res, vol. 48, no. 5, pp. 337-344, Apr, 2018.
[62] M. S. Mohamed, A. S. Hanafy, M. A. A. Bassiony, and S. Hussein, “Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients,” European Journal of Gastroenterology & Hepatology, vol. 29, no. 12, pp. 1368-1372, Dec, 2017.
[63] T. Kan, S. Hashimoto, N. Kawabe, T. Nakano, K. Nakaoka, and K. Yoshioka, “Increase in Albumin by Daclatasvir/asunaprevir Therapy is Correlated with Decrease in Aspartate Transaminase,” J Transl Int Med, vol. 5, no. 3, pp. 148-154, Sep, 2017.
[64] H. J. Moshage, J. A. Janssen, J. H. Franssen, J. C. Hafkenscheid, and S. H. Yap, “Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation,” J Clin Invest, vol. 79, no. 6, pp. 1635-41, Jun, 1987.
[65] S. Murata, N. Ohkohchi, R. Matsuo, O. Ikeda, A. Myronovych, and R. Hoshi, “Platelets promote liver regeneration in early period after hepatectomy in mice,” World journal of surgery, vol. 31, no. 4, pp. 808- 816, 2007.
[66] T. Yoshizumi, S. Itoh, D. Imai, T. Ikegami, M. Ninomiya, T. Iguchi, N. Harimoto, K. Takeishi, Y. Kimura, H. Uchiyama, Y. Soejima, T. Ikeda, H. Kawanaka, K. Shirabe, and Y. Maehara, “Impact of platelets and serotonin on liver regeneration after living donor hepatectomy,” Transplant Proc, vol. 47, no. 3, pp. 683-5, Apr, 2015.
[67] S. V. Sasturkar, P. David, S. Sharma, S. K. Sarin, N. Trehanpati, and V. Pamecha, “Serial changes of cytokines and growth factors in peripheral circulation after right lobe donor hepatectomy,” Liver Transpl, vol. 22, no. 3, pp. 344-51, Mar, 2016.
[68] A. Mallat, A. M. Preaux, S. Blazejewski, J. Rosenbaum, D. Dhumeaux, and P. Mavier, “Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture,” Hepatology, vol. 21, no. 4, pp. 1003-10, Apr, 1995.
[69] J. A. Fitzpatrick, J. U. Kim, J. F. Cobbold, M. J. McPhail, M. M. Crossey, A. A. Bak-Bol, A. Zaky, and S. D. Taylor-Robinson, “Changes in Liver Volume in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy,” J Clin Exp Hepatol, vol. 6, no. 1, pp. 15-20, Mar, 2016.
[70] Y. Shiratori, F. Imazeki, M. Moriyama, M. Yano, Y. Arakawa, O. Yokosuka, T. Kuroki, S. Nishiguchi, M. Sata, G. Yamada, S. Fujiyama, H. Yoshida, and M. Omata, “Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy,” Ann Intern Med, vol. 132, no. 7, pp. 517-24, Apr 4, 2000.